XERS - ゼリス・ファ―マシュ―ティカルズ （Xeris Pharmaceuticals Inc.）

Xeris Biopharma (XERS) said that the U.S. Patent and Trademark Office issued a patent covering its XeriSol formulations. Read more here

https://www.investing.com/news/assorted/xeris-pharmaceuticals-issued-us-patent-covering-xerisol-formulations-432SI-3057885

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the U.S. Patent and Trademark Office has issued US Patent Number 11,590,205, entitled ‘METHODS FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN APROTIC

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the U.S. Patent and Trademark Office has issued US Patent Number 11,590,205, entitled ‘METHODS FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN APROTIC POLAR SOLVENTS.’ The claims in this newly issued patent cover certain pharmace

Xeris Biopharma Holdings Inc. (NASDAQ:XERS)’s traded shares stood at 1.64 million during the last session, with the company’s beta value hitting 1.30. At the close of trading, the stock’s price was $1.89, to imply a decrease of -2.58% or -$0.05 in intraday trading. The XERS share’s 52-week high remains $2.72, putting it -43.92% down since … Xeris Biopharma Holdings Inc. At $1.89: Buy, Sell Or Hold? Read More »

Xeris Biopharma Holdings Inc. (NASDAQ:XERS)’s traded shares stood at 1.64 million during the last session, with the company’s beta value hitting 1.30. At the close of trading, the stock’s price was $1.89, to imply a decrease of -2.58% or -$0.05 in intraday trading. The XERS share’s 52-week high remains $2.72, putting it -43.92% down since … Xeris Biopharma Holdings Inc. At $1.89: Buy, Sell Or Hold? Read More »

Xeris Biopharma (XERS) has inked an agreement with Regeneron (REGN) to use its drug-formulation platform, XeriJect, to develop monoclonal antibodies. Read more here.

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and comm

Xeris Biopharma''s shares have lost over half their value during the past year. Click here to see why XERS stock is a Buy.

Xeris Biopharma (XERS) stock fell ~10% on Wednesday despite Q4 results beat estimates.Net loss narrowed to -$12.93M, compared to -$50.79M in Q4 2021.Total revenue grew +54.6% to $33.14

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that, based on feedback from a Type C meeting with the Food and Drug Administration (FDA), Xeris will proceed with a Phase II study in patients for its novel formulation

Xeris Biopharma Holdings Inc. (NASDAQ:XERS) concluded the trading at $1.32 on Wednesday, November 23 with a rise of 3.94% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $1.27 with its price kept floating in the range of $1.28 and $1.43 on … Analyst Updating Price Targets And Ratings For Xeris Biopharma Holdings Inc. (XERS) Read More »

Xeris Biopharma (XERS) said it entered a research collaboration and option agreement with Horizon Therapeutics (HZNP) for XeriJect formulation of teprotumumab,Teprotumumab-trbw is sold…

Xeris to develop an ultra-concentrated, ready-to-use, subcutaneous injection of teprotumumab … | November 23, 2022

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (Nasdaq: HZNP). Under the terms of the agreement, Xeris will use its